Challenges in the Evaluation of HER2 and HER2-low in Breast Cancer in Brazil and Recommendations of a Multidisciplinary Working Group

Overview

Journal Rev Assoc Med Bras (1992)

Specialty General Medicine

Date 2024 Oct 2

PMID 39356956

Authors

Helenice Gobbi

Filomena Marino Carvalho

Marina De Brot

Angela Flavia Logullo

Carlos Augusto Moreira Silva

Fernando Augusto Soares

Luciana Landeiro

Rosemar Rahal

Carlos Henrique Barrios

Affiliations

Soon will be listed here.

References

Bergeron A, Bertaut A, Beltjens F, Charon-Barra C, Amet A, Jankowski C . Anticipating changes in the HER2 status of breast tumours with disease progression-towards better treatment decisions in the new era of HER2-low breast cancers. Br J Cancer. 2023; 129(1):122-134. PMC: 10307899. DOI: 10.1038/s41416-023-02287-x. View

Mosele F, Deluche E, Lusque A, Le Bescond L, Filleron T, Pradat Y . Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023; 29(8):2110-2120. PMC: 10427426. DOI: 10.1038/s41591-023-02478-2. View

Salinas M, Lopez-Garrigos M, Yago M, Ortuno M, Carratala A, Aguado C . [Quality assessment for preanalytical phase in clinical laboratory: a multicentric study]. Rev Calid Asist. 2011; 26(4):264-8. DOI: 10.1016/j.cali.2011.03.008. View

Fernandez A, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K . Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. JAMA Oncol. 2022; 8(4):1-4. PMC: 8814969. DOI: 10.1001/jamaoncol.2021.7239. View

Bardia A, Viale G . HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast. Target Oncol. 2023; 18(3):313-319. PMC: 10191945. DOI: 10.1007/s11523-023-00964-8. View

Garrido C, Manoogian M, Ghambire D, Lucas S, Karnoub M, Olson M . Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer. Virchows Arch. 2023; 484(6):1005-1014. PMC: 11186906. DOI: 10.1007/s00428-023-03671-x. View

Anderson B, Ilbawi A, Fidarova E, Weiderpass E, Stevens L, Abdel-Wahab M . The Global Breast Cancer Initiative: a strategic collaboration to strengthen health care for non-communicable diseases. Lancet Oncol. 2021; 22(5):578-581. DOI: 10.1016/S1470-2045(21)00071-1. View

Ahn J, Shin S, Yang S, Park E, Kim K, Cho S . Artificial Intelligence in Breast Cancer Diagnosis and Personalized Medicine. J Breast Cancer. 2023; 26(5):405-435. PMC: 10625863. DOI: 10.4048/jbc.2023.26.e45. View

Krop I, LoRusso P, Miller K, Modi S, Yardley D, Rodriguez G . A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012; 30(26):3234-41. DOI: 10.1200/JCO.2011.40.5902. View

10.

Plebani M, Sciacovelli L, Aita A, Pelloso M, Chiozza M . Performance criteria and quality indicators for the pre-analytical phase. Clin Chem Lab Med. 2015; 53(6):943-8. DOI: 10.1515/cclm-2014-1124. View

11.

Najjar S, Allison K . Updates on breast biomarkers. Virchows Arch. 2022; 480(1):163-176. DOI: 10.1007/s00428-022-03267-x. View

12.

Wolff A, Somerfield M, Dowsett M, Hammond M, Hayes D, McShane L . Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol. 2023; 41(22):3867-3872. DOI: 10.1200/JCO.22.02864. View

13.

Robbins C, Fernandez A, Han G, Wong S, Harigopal M, Podoll M . Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry. Mod Pathol. 2023; 36(1):100032. PMC: 10278086. DOI: 10.1016/j.modpat.2022.100032. View

14.

Francies F, Hull R, Khanyile R, Dlamini Z . Breast cancer in low-middle income countries: abnormality in splicing and lack of targeted treatment options. Am J Cancer Res. 2020; 10(5):1568-1591. PMC: 7269781. View

15.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

16.

Moutafi M, Robbins C, Yaghoobi V, Fernandez A, Martinez-Morilla S, Xirou V . Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer. Lab Invest. 2022; 102(10):1101-1108. DOI: 10.1038/s41374-022-00804-9. View

17.

Wolff A, Hammond M, Allison K, Harvey B, Mangu P, Bartlett J . Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018; 36(20):2105-2122. DOI: 10.1200/JCO.2018.77.8738. View

18.

Tarantino P, Hamilton E, Tolaney S, Cortes J, Morganti S, Ferraro E . HER2-Low Breast Cancer: Pathological and Clinical Landscape. J Clin Oncol. 2020; 38(17):1951-1962. DOI: 10.1200/JCO.19.02488. View

19.

Viale G, Basik M, Niikura N, Tokunaga E, Brucker S, Penault-Llorca F . Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer. ESMO Open. 2023; 8(4):101615. PMC: 10515285. DOI: 10.1016/j.esmoop.2023.101615. View

20.

Esposito A, Criscitiello C, Curigliano G . Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer. Ecancermedicalscience. 2015; 9:518. PMC: 4404037. DOI: 10.3332/ecancer.2015.518. View